EHA 2017- European Hematology Association - June 22-25, 2017
Chronic Myeloid Leukemia - CML -22th Congress of EHA
SOME INTERESTING ABSTRACTS FOR CML
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB
A CASE OF ATYPICAL CHRONIC MYELOID LEUKEMIA WITH LATE DISCOVERY OF JAK2
OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA
ANALYSIS OF VASCULAR ADVERSE EVENTS IN TKI TREATED JAPANESE CML PATIENTS: RETROSPECTIVE LARGE COHORT STUDY OF CML COOPERATIVE STUDY GROUP
QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE INHIBITORS
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL
BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB
A CASE OF ATYPICAL CHRONIC MYELOID LEUKEMIA WITH LATE DISCOVERY OF JAK2
OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA
ANALYSIS OF VASCULAR ADVERSE EVENTS IN TKI TREATED JAPANESE CML PATIENTS: RETROSPECTIVE LARGE COHORT STUDY OF CML COOPERATIVE STUDY GROUP
QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE INHIBITORS